DIAN

Back to Clinical Research Studies

Who can be involved:

WA only

  • Male or female, aged ≥18 years inclusive, at the time of informed consent
  • Has a parent, or a brother or sister, with a genetic mutation causing early onset Alzheimer’s disease
  • Has an identified, reliable, study partner
  • Willingness to undergo study procedures.
  • Ability and willingness to provide written informed consent

This study will identify the biological changes that occur in the development of Alzheimer’s disease to improve early diagnosis and to track progression of the disease. Researchers will collect biological information from adults who have parents with a known inheritable, genetic mutation for Alzheimer’s disease, specifically mutations in presenilin 1 (PSEN1), presenilin 2 (PSEN2), and amyloid precursor protein (APP) genes. Researchers will measure the amount of abnormal amyloid in the brain and spinal fluid, changes in brain size (e.g. shrinkage), and brain metabolism (energy processing). They will compare the changes that occur in participants with and without mild Alzheimer’s symptoms, who may or may not have an Alzheimer’s genetic mutation.

What is involved:

  • Bi-annual in-person assessments, with a remote assessment in the in-between years
  • Participants will undergo clinical examination, neurological examination, memory testing, genetic testing, brain imaging, and provide blood and (optional) spinal fluid samples.

Additional info:

For further information about the DIAN Study please contact Dr Samantha Gardener, Clinical Trial Coordinator at (08) 6457 0419 or email s.gardener@ecu.edu.au.